Sunshine Biopharma SBFM 深 滬
交易中 10-08 10:52:45 美东时间
0.4337
-0.266
-38.04%
華盛通- 最 高0.47
- 今 開0.47
- 成交量 1.04亿股
- 最 低 0.4006
- 昨 收 0.70
- 總市值 186.94万
- 52周最高 23.20
- 市盈率 靜 --
- 換手率 2402.81%
- 52周最低 0.3564
- 委 比 0.00%
- 總股本 431.03万
- 歷史最高 197400.00
- 量 比 16.32
- 振 幅 9.91%
- 歷史最低 0.4006
- 每 手 1
- 風險率 5.98%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Sunshine Biopharma announces pricing of $6M public offering
Sunshine Biopharma (SBFM) on Thursday announced the pricing of a public offering made on a reasonable best efforts basis with gross proceeds to the company expected to be about $6 million. The offerin...
今天 20:17
Sunshine Biopharma Launches Generic Ondansetron Tablets Of 4mg And 8mg In Canadian Market
Launch introduces ondansetron 4 mg and 8 mg tablets for nausea and vomiting associated with chemotherapy, radiation therapy and surgery Global ondansetron market projected to reach $2.98 billion by 2034, up from $1.82 billion in 2025, according to DataIntelo Commercial rollout supported by Nora Phar...
09-24 21:02
Sunshine Biopharma Says CEO Steve Slilaty, Holder Of About 97% Of Voting Power, Approved Reverse Stock Split Of Up To 1-For-20 By Written Consent
https://www.sec.gov/ix?doc=/Archives/edgar/data/0001402328/000168316826007193/sunshine_8k.htm https://www.sec.gov/Archives/edgar/data/1402328/000168316826007195/sunshine_pre14c.htm
09-17 04:17
Sunshine Biopharma Adjusts Series B Warrant Exercise Price
Sunshine Biopharma ( ($SBFM) ) has provided an update. As of the date of the fi...
09-12 05:27
Sunshine Biopharma Announces Updates On Its K1.1 mRNA Tumor Suppressor; Outlines Plans For Program
Sunshine Biopharma Inc. (NASDAQ:SBFM) (the "Company"), a leading pharmaceutical company offering and researching life-saving medicines across multiple therapeutic areas including oncology and antivirals, today provided an update and outlined next plans for its oncology project, the K1.1 mRNA lipid n...
08-26 21:03
EXCLUSIVE: Sunshine Biopharma Advances Vaccine Strategy for Lung Cancer
Sunshine Biopharma Inc. (NASDAQ:SBFM) on Wednesday released an update regarding its proprietary oncology initiative, outlining key next steps for its K1.1 mRNA lipid nanoparticle program. K1.1 mRNA Preclinical Results The K1.1 mRNA gene acts as a tumor suppressor frequently mutated in hepatocellular...
08-26 20:31
Sunshine Biopharma Announces Approval Of Generic Enalapril Tablets 2.5mg, 5mg, 10mg And 20mg For Canadian Market
Global anti-hypertensive drug market projected to reach $37.24 billion by 2034 Enalapril is a widely prescribed ACE inhibitor used to treat hypertension, heart failure and left ventricular dysfunction Sunshine Biopharma expects Enalapril tablets in four dosage strengths to begin shipping to Canadian...
08-19 21:02
EXCLUSIVE: Sunshine Biopharma Secures Canadian Approval for Generic Hypertension Drug
Sunshine Biopharma Inc. (NASDAQ:SBFM) announced on Wednesday that it has secured regulatory approval to introduce its generic Enalapril tablets across the Canadian market, signaling a significant strategic step into first-line antihypertensive treatments. The newly approved medication, the generic e...
08-19 20:30
EXCLUSIVE: Sunshine Biopharma Targets Canadian Market with New Women's Health Drug Approval
Pharmaceutical firm Sunshine Biopharma Inc. (NASDAQ:SBFM) on Tuesday said it received regulatory approval to introduce its 2mg generic Dienogest tablets to the Canadian market. The significant milestone marks the company’s strategic expansion into women’s healthcare, specifically targeting first-lin...
08-04 20:31
Sunshine Biopharma Announces Approval Of Generic Anastrozole Tablets Of 1mg For Canadian Market
Sunshine Biopharma Inc. (NASDAQ:SBFM) (the "Company"), a leading pharmaceutical company specializing in generic and specialty prescription medications, is pleased to announce the approval of its generic Anastrozole tablets of 1mg for the Canadian market. Anastrozole is the generic equivalent of the ...
06-25 20:03
